Literature DB >> 29042490

Remote Ischemic Conditioning May Improve Outcomes of Patients With Cerebral Small-Vessel Disease.

Yuan Wang1, Ran Meng1, Haiqing Song1, Gang Liu1, Yang Hua1, Dehua Cui1, Lemin Zheng1, Wuwei Feng1, David S Liebeskind1, Marc Fisher1, Xunming Ji2.   

Abstract

BACKGROUND AND
PURPOSE: We aimed to evaluate the efficacy of remote ischemic conditioning (RIC) in patients with cerebral small-vessel disease.
METHODS: Thirty patients with cerebral small-vessel disease-related mild cognitive impairment were enrolled in this prospective, randomized controlled study for 1 year. Besides routine medical treatment, participants were randomized into the experimental group (n=14) undergoing 5 cycles consisting of ischemia followed by reperfusion for 5 minutes on both upper limbs twice daily for 1 year or the control group (n=16) who were treated with sham ischemia-reperfusion cycles. The primary outcome was the change of brain lesions, and secondary outcomes were changes of cognitive function, plasma biomarkers, and cerebral hemodynamic parameters both at baseline and at the end of 1-year follow-up.
RESULTS: Compared with pretreatment, the post-treatment white matter hyperintensities volume in the RIC group was significantly reduced (9.10±7.42 versus 6.46±6.05 cm3; P=0.020), whereas no significant difference was observed in the sham-RIC group (8.99±6.81 versus 8.07±6.56 cm3; P=0.085). The reduction of white matter hyperintensities volume in the RIC group was more substantial than that in sham group (-2.632 versus -0.935 cm3; P=0.049). No significant difference was found in the change of the number of lacunes between 2 groups (0 versus 0; P=0.694). A significant treatment difference at 1 year on visuospatial and executive ability was found between the 2 groups (0.639 versus 0.191; P=0.048). RIC showed greater effects compared with sham-RIC on plasma triglyceride (-0.433 versus 0.236 mmol/L; P=0.005), total cholesterol (-0.975 versus 0.134 mmol/L; P<0.001), low-density lipoprotein (-0.645 versus -0.029 mmol/L; P=0.034), and homocysteine (-4.737 versus -1.679 µmol/L; P=0.044). Changes of the pulsation indices of middle cerebral arteries from the baseline to 1 year were different between the 2 groups (right: -0.075 versus 0.043; P=0.030; left: -0.085 versus 0.043; P=0.010).
CONCLUSIONS: RIC seems to be potentially effective in patients with cerebral small-vessel disease in slowing cognition decline and reducing white matter hyperintensities. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01658306.
© 2017 American Heart Association, Inc.

Entities:  

Keywords:  cerebral small vessel diseases; cognition; risk factors; stroke

Mesh:

Year:  2017        PMID: 29042490     DOI: 10.1161/STROKEAHA.117.017691

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  44 in total

1.  Ischemic conditioning increases strength and volitional activation of paretic muscle in chronic stroke: a pilot study.

Authors:  Allison S Hyngstrom; Spencer A Murphy; Jennifer Nguyen; Brian D Schmit; Francesco Negro; David D Gutterman; Matthew J Durand
Journal:  J Appl Physiol (1985)       Date:  2018-02-08

Review 2.  Advances in chronic cerebral circulation insufficiency.

Authors:  Da Zhou; Ran Meng; Si-Jie Li; Jing-Yuan Ya; Jia-Yue Ding; Shu-Ling Shang; Yu-Chuan Ding; Xun-Ming Ji
Journal:  CNS Neurosci Ther       Date:  2017-11-15       Impact factor: 5.243

Review 3.  Endogenous neuroprotective potential due to preconditioning exercise in stroke.

Authors:  Harutoshi Sakakima
Journal:  Phys Ther Res       Date:  2019-09-06

4.  A meta-analysis of remote ischaemic conditioning in experimental stroke.

Authors:  Philippa Weir; Ryan Maguire; Saoirse E O'Sullivan; Timothy J England
Journal:  J Cereb Blood Flow Metab       Date:  2020-06-14       Impact factor: 6.200

5.  Thrombin-induced tolerance against oxygen-glucose deprivation in astrocytes: role of protease-activated receptor-1.

Authors:  Xuhui Bao; Ya Hua; Richard F Keep; Guohua Xi
Journal:  Cond Med       Date:  2018-02-15

6.  Effect of Remote Ischemic Conditioning vs Usual Care on Neurologic Function in Patients With Acute Moderate Ischemic Stroke: The RICAMIS Randomized Clinical Trial.

Authors:  Hui-Sheng Chen; Yu Cui; Xiao-Qiu Li; Xin-Hong Wang; Yu-Tong Ma; Yong Zhao; Jing Han; Chang-Qing Deng; Mei Hong; Ying Bao; Li-Hong Zhao; Ting-Guang Yan; Ren-Lin Zou; Hui Wang; Zhuo Li; Li-Shu Wan; Li Zhang; Lian-Qiang Wang; Li-Yan Guo; Ming-Nan Li; Dong-Qing Wang; Qiang Zhang; Da-Wei Chang; Hong-Li Zhang; Jing Sun; Chong Meng; Zai-Hui Zhang; Li-Ying Shen; Li Ma; Gui-Chun Wang; Run-Hui Li; Ling Zhang; Cheng Bi; Li-Yun Wang; Duo-Lao Wang
Journal:  JAMA       Date:  2022-08-16       Impact factor: 157.335

Review 7.  Optical ultrasound sensors for photoacoustic imaging: a narrative review.

Authors:  Bo Fu; Yuan Cheng; Ce Shang; Jing Li; Gang Wang; Chenghong Zhang; Jingxuan Sun; Jianguo Ma; Xunming Ji; Boqu He
Journal:  Quant Imaging Med Surg       Date:  2022-02

8.  Association of sickle cell trait with measures of cognitive function and dementia in African Americans.

Authors:  Nemin Chen; Christina Caruso; Alvaro Alonso; Vimal K Derebail; Abhijit V Kshirsagar; A Richey Sharrett; Nigel S Key; Rebecca F Gottesman; Megan L Grove; Jan Bressler; Eric Boerwinkle; B Gwen Windham; Thomas H Mosley; Hyacinth I Hyacinth
Journal:  eNeurologicalSci       Date:  2019-07-22

Review 9.  Remote ischaemic conditioning for stroke: unanswered questions and future directions.

Authors:  Sheharyar Baig; Bethany Moyle; Krishnan Padmakumari Sivaraman Nair; Jessica Redgrave; Arshad Majid; Ali Ali
Journal:  Stroke Vasc Neurol       Date:  2021-04-26

10.  Limb Remote Ischemic Conditioning Ameliorates Cognitive Impairment in Rats with Chronic Cerebral Hypoperfusion by Regulating Glucose Transport.

Authors:  Changhong Ren; Yuanyuan Liu; Christopher Stone; Ning Li; Sijie Li; Haiyan Li; Zichao Cheng; Jiangnan Hu; Weiguang Li; Kunlin Jin; Xunming Ji; Yuchuan Ding
Journal:  Aging Dis       Date:  2021-08-01       Impact factor: 6.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.